Genome-wide multi-omics profiling of colorectal cancer identifies immune determinants strongly associated with relapse

The use and benefit of adjuvant chemotherapy to treat stage II colorectal cancer (CRC) patients is not well understood since the majority of these patients are cured by surgery alone. Identification of biological markers of relapse is a critical challenge to effectively target treatments to the ~20%...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhavan, Subha, Gusev, Yuriy, Natarajan, Thanemozhi G., Song, Lei, Bhuvaneshwar, Krithika, Gauba, Robinder, Pandey, Abhishek, Haddad, Bassem R., Goerlitz, David, Cheema, Amrita K., Juhl, Hartmut, Kallakury, Bhaskar, Marshall, John L., Byers, Stephen W., Weiner, Louis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834519/
https://www.ncbi.nlm.nih.gov/pubmed/24312117
http://dx.doi.org/10.3389/fgene.2013.00236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834519/
https://www.ncbi.nlm.nih.gov/pubmed/24312117
http://dx.doi.org/10.3389/fgene.2013.00236

Ejemplares similares